Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. (15th June 2020)

• Record Type: Journal Article
• Authors: Daniels, K.; van der Nat, P. B.; Frequin, S. T. F. M.; van der Wees, P. J.; Biesma, D. H.; Hoogervorst, E. L. J.; van de Garde, E. M. W.
• Other Names: Calabrese Pasquale Academic Editor.
• Is Part Of: Multiple sclerosis international. Volume 2020(2020)
• Publication Date: 2020-06-15
• Subjects: Multiple sclerosis -- Periodicals; 616.834005
• DOI: 10.1155/2020/5463451
• Languages: English
• ISSNs: 2090-2654

Abstract

Abstract : Background . Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered. Objective . The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting. Methods . We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21 ) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration). Results . Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = − 2.81, p ≤ .01 ). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start. Conclusion . Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.